Unfortunately, there is limited information regarding this reversal approach. Management guidelines are based on the level of urgency, severity and/or place of bleeding. There is a need for an antidote which reverses this risk of bleeding from use or overuse of DOACs as well as to prevent bleeding associated with DOACs in patients undergoing emergency or elective surgery. However, inappropriate use of DOACs may increase the risk of bleeding. Specific antidote, DOACs, idarucizumab, andexanet alfa, ciraparantag AbstractĬurrently, the use of Direct Oral Anticoagulants (DOACs) has become more common place since this group of drugs was developed to overcome the limitations of warfarin.
Department of Pharmacy, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
0 kommentar(er)
